Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 1, 2011, Pages 135-144

  Bose, Sujoy ^a   Sakhuja, Puja ^a   Bezawada, Lavanaya ^c   Agarwal, Anil K ^a   Kazim, Seyed N ^a,b   Khan, Luqman A ^b   Sarin, Shiv K ^a   Ramakrishna, Gayatri ^c  

^a G B PANT HOSPITAL   (India)

^b JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^c CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

Author keywords

Hep3B; Hepatitis B virus; Hepatocellular carcinoma; HepG2; Ras; Tumor heterogeneity

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; VIRUS DNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CODON; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DNA VIRUS; DOWN REGULATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PATHOGENESIS; PERSISTENT INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WILD TYPE;

EID: 78650385124     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06305.x     Document Type: Article

References (38)

1. Befeler AS, Di Bisceglie AM. Hepatitis B. Infect. Dis. Clin. North Am. 2000; 14: 617-32.
2. Hollinger FB, Liang TJ. Hepatitis B virus. In: Knipe DM, Howley PM, eds. Field's Virology, 4th edn. Philadelphia, PA: Lippincott, Williams and Wilkins, 2001; 2971-3036.
3. Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J. Viral. Hepat. 2004; 11: 383-93.
4. Siddiqui A, Jameel S, Mapoles JE. Expression of the hepatitis B viral X gene. Proc. Natl. Acad. Sci. USA 1987; 84: 2513-17.
5. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures: a review. J. Viral Hepat. 2004; 11: 97-107.
6. Datta, S. An overview of molecular epidemiology of hepatitis B virus (HBV) in India. Virol. J. 2008; 19: 156.
7. Schlaeger C, Longerich T, Schiller C et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 2008; 47: 511-20.
8. Ching YP, Leong VY, Lee MF, Xu, HT, Jin DY, Ng IO. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res. 2007; 67: 3601-8.
9. Calvisi DF, Ladu S, Gorden A et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130 (4): 1117-28.
10. Calvisi DF, Ladu S, Gorden A et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J. Clin. Invest. 2007; 117: 2713-22.
11. Bengochea A, de Souza MM, Lefrançois L et al. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br. J. Cancer 2008; 99: 143-50.
12. Arsura M, Cavin LG. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett. 2005; 229: 157-69.
13. Nakajima T, Yasui K, Zen K et al. Activation of B-Myb by E2F1 in hepatocellular carcinoma. Hepatol. Res. 2008; 38: 886-95.
14. Yoon YJ, Chang HY, Ahn SH et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008; 29: 1192-6.
15. Saxena N, Lahiri, SS, Hambarde S, Tripathi RP. RAS: Target for Cancer Therapy. Cancer Invest. 2008; 26: 948-55.
16. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 2008; 9: 517-31.
17. Singh A, Sowjanya AP, Ramakrishna G. The wild-type Ras: road ahead. FASEB J. 2005; 19: 161-9.
18. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
19. Spandidos A, Wilkie NM. The normal human H-ras1 gene can act as an onco-suppressor. Br. J. Cancer Suppl. 1988; 9: 67-71.
20. Spandidos DA, Frame M, Wilkie NM. Expression of the normal H-ras1 gene can suppress the transformed and tumorigenic phenotypes induced by mutant ras genes. Anticancer Res. 1990; 10: 1543-54.
21. Zhang Z, Wang Y, Vikis HG et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 2001; 29: 25-33.
22. Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signalling cascade. Proc. Natl. Acad. Sci. USA 1994; 91: 10350-4.
23. Natoli G, Avantaggiati ML, Chirillo P et al. Ras- and Raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX. Oncogene 1994; 9: 2837-43.
24. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J. Gastroenterol. Hepatol. 2002; 17: 165-70.
25. Krischberg O, Schuttler C, Repp R, Schaefer S. A multiplex-PCR to identify hepatitis B virus-genotypes A-F. J. Clin. Virol. 2004; 29: 39-43.
26. Taylor SJ, Resnick RJ, Shalloway D. Nonradioactive determination of Ras-GTP levels using activated ras interaction assay. Methods Enzymol. 2001; 333: 333-42.
27. Yang HI, Yeh SH, Chen PJ et al. REVEAL-HBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl. Cancer Inst. 2008; 100: 1134-43.
28. Luo D, Liu QF, Gove C, Naomov N, Su JJ, Williams R. Analysis of N-ras gene mutation and p53 gene expression in human HCC. World J. Gastroenterol. 1998; 4: 97-9.
29. Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. Frequent k- ras -2 mutations and p16(INK4A)methylation in HCC in workers exposed to vinyl chloride. Br. J. Cancer 2001; 84: 982-9.
30. Uchiyama M, Usami N, Kondo M et al. Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer. Int. J. Cancer 2003; 107: 962-9.
31. Moghaddam SJ, Haghighi EN, Samiee S et al. Immunohistochemical analysis of p53, cyclinD1, RB1, c-fos and N-ras gene expression in hepatocellular carcinoma in Iran. World J. Gastroenterol. 2007; 13: 588-93.
32. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 2006; 25: 3823-33.
33. Wu CG, Salvay DM, Forgues M et al. Distinctive gene expression profiles associated with Hepatitis B virus x protein. Oncogene 2001; 20: 3674-82.
34. Braig M, Lee S, Loddenkemper C et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005; 436 (7051): 636-7.
35. Collado M, Gil J, Efeyan A et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436: 642.
36. Gumucio JJ. Hepatocyte heterogeneity: the coming of age from the description of a biological curiosity to a partial understanding of its physiological meaning and regulation. Hepatology 1989; 9: 154-60.
37. Llovet JM, Ricci S, Mazzaferro V et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-90.
38. Heng HH. Cancer genome sequencing: the challenges ahead. Bioessays 2007; 29: 783-94.